ONCY (Oncolytics Biotech Inc.) stock: $0.44, $57.6M market cap, $4.1M cash, $53.5M EV, $62.9M fully diluted market cap. Lead program: Paclitaxel (Breast Cancer Metastatic), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. We expect our current cash resources to be able to fund near-term milestones, but they are not sufficient to fund our planned operations over the next 12 months from the date of issuance of our consolidated financial statements included in this Annual Report.
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Common
127.5M
Pre-funded warrants
0.0M
Options
7.3M
RSUs
0.0M
Warrants
8.2M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.0M
FDSO
143.1M
Cap table as of 2026-06-30.
Price history
Loading ONCY daily closes…
Loading price history…
Next catalyst
Pelareorep · Sep 10 - Oct 22 in 10 mo · Phase 1/2 · Anal Cancer Metastatic; Squamous Cell Carcinoma of the Anus Stage Unspecified; Pancreatic Cancer Metastatic
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Adlai Nortye Biopharma: exclusive development/commercialization rights in China, Hong Kong, Macau, Singapore, South Korea, Taiwan. PanCAN: Therapeutic Accelerator Award (up to $5M) funding a pelareorep pancreatic cancer trial. National Research Council of Canada: manufacturing collaboration.
2L+ squamous cell carcinoma of the anal canal(Phase 2)
Metastatic pancreatic ductal adenocarcinoma(Stage not disclosed)
Catalysts
— 2026 (fall/winter)
Status note Lead and only clinical asset. REO 033 randomized Phase 2 in 2L RAS-mutant MSS mCRC launched Mar 2026 (first site early Apr 2026); FDA Fast Track granted Q1 2026. GOBLET Cohort 4 in relapsed unresectable SCAC completed enrollment; Type C FDA meeting (Apr 2026) held on pivotal 2L+ SCAC trial; FDA Fast Track granted Jul 2026. Evaluating strategic options for registrational mPDAC program.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.